Results
Results shown according to disease and biological agents
SAD |
Biological agent |
Nº patients |
Therapeutic response n (%) |
Side effects n (%) |
Mortalty
n (%) |
|---|---|---|---|---|---|
Behçet |
Infliximab |
6 |
4 (67%) |
0 (0%) |
0 (0%) |
Etanercept (2) |
2 |
1 (50%) |
1 (50%) |
0 (0%) |
|
Crioglobulinemia |
Rituximab |
2 |
2 (100%) |
0 (0%) |
1 (50%) |
Dermatomyositis |
Etanercept (1) |
3 |
2/2 (100%) |
1 (33%) |
0 (0%) |
Infliximab (1) |
2 |
1 (50%) |
2 (100%) |
0(0%) |
|
Rituximab |
3 |
2 (67%) |
0 (0%) |
1 (33%) |
|
Sclerodermia |
Rituximab |
1 |
1 (100%) |
0 (0%) |
0 (0%) |
SLE |
Riuximab |
24 |
19/23 (83%) |
5 (20%) |
0 (0%) |
MPA |
Rituximab |
1 |
1 (100%) |
0 (0%) |
0 (0%) |
Etanercept |
1 |
1 (100%) |
0 (0%) |
0 (0%) |
|
PAN |
Infliximab |
2 |
1 (50%) |
1 (50%) |
0 (0%) |
Adalimumab (1) |
1 |
1 (100%) |
0 (0%) |
0 (0%) |
|
Rituximab (1) |
1 |
1 (100%) |
0 (0%) |
0 (0%) |
|
Policondritis |
Infliximab |
1 |
0 (0%) |
0 (0%) |
0 (0%) |
Adalimumabt |
1 |
0 (0%) |
0 (0%) |
0 (0%) |
|
APS |
Rituximab |
2 |
1 (50%) |
1 (50%) |
0 (0%) |
Sjögren |
Rituximab |
7 |
7 (100%) |
1 (14%) |
0 (0%) |
Still’s Disease |
Infliximab |
3 |
3 (100%) |
1 (33%) |
0 (0%) |
Vogt-Koyanagi |
Infliximab |
1 |
0 (0%) |
0 (0%) |
0 (0%) |
Wegener |
Rituximab |
6 |
4 (66%) |
1 (17%) |
1 (17%) |
Etanercept (2) |
2 |
1 (50%) |
0 (0%) |
0 (0%) |
SYSTEMIC AUTOIMMUNE DISEASES
BIOLOGICAL AGENTS ADMINISTERED
